Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Thorgeirsson Website

Snorri S. Thorgeirsson, M.D., Ph.D.

Selected Publications

1)  Kitade M, Factor VM, Andersen JB, Tomokuni A, Kaji K, Akita H, Holczbauer A, Seo D, Marquardt JU, Conner EA, Lee SB, Lee YH, Thorgeirsson SS.
Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling.
Genes Dev. 27: 1706-17, 2013.
[Journal]
2)  Andersen JB, Thorgeirsson SS.
Genomic decoding of intrahepatic cholangiocarcinoma reveals therapeutic opportunities.
Gastroenterology. 144: 687-90, 2013.
[Journal]
3)  Holczbauer A, Factor VM, Andersen JB, Marquardt JU, Kleiner D, Raggi C, Kitade M, Seo D, Akita H, Durkin M, Thorgeirsson SS.
Modeling Pathogenesis of Primary Liver Cancer in Lineage-Specific Mouse Cell Types.
Gastroenterology. [Epub ahead of print], 2013.
[Journal]
4)  Lee SB, Seo D, Choi D, Park KY, Holczbauer A, Marquardt JU, Conner EA, Factor VM, Thorgeirsson SS.
Contribution of hepatic lineage stage-specific donor memory to the differential potential of induced mouse pluripotent stem cells.
Stem Cells. 30: 997-1007, 2012.
[Journal]
5)  Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS.
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Gastroenterology. 142: 1021-1031.e15, 2012.
[Journal]
6)  Ishikawa T, Factor VM, Marquardt JU, Raggi C, Seo D, Kitade M, Conner EA, Thorgeirsson SS.
Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice.
Hepatology. 55: 1215-26, 2012.
[Journal]
7)  Jia J, Parikh H, Xiao W, Hoskins JW, Pflicke H, Liu X, Collins I, Zhou W, Wang Z, Powell J, Thorgeirsson SS, Rudloff U, Petersen GM, Amundadottir LT.
An integrated transcriptome and epigenome analysis identifies a novel candidate gene for pancreatic cancer.
BMC Med Genomics. 6: 33, 2013.
[Journal]
8)  Clavijo-Cornejo D, Enriquez-Cortina C, López-Reyes A, Domínguez-Pérez M, Nuño N, Domínguez-Meraz M, Bucio L, Souza V, Factor VM, Thorgeirsson SS, Gutiérrez-Ruiz MC, Gómez-Quiroz LE.
Biphasic regulation of the NADPH oxidase by HGF/c-Met signaling pathway in primary mouse hepatocytes.
Biochimie. [Epub ahead of print], 2013.
[Journal]
9)  Staib F, Krupp M, Maass T, Itzel T, Weinmann A, Lee JS, Schmidt B, Müller M, Thorgeirsson SS, Galle PR, Teufel A.
CellMinerHCC: a microarray-based expression database for hepatocellular carcinoma cell lines.
Liver Int. 2013.
[Journal]
10)  Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, Park J, Lu P, Hsia CC, Wang N, Xu L, Lu L, Huang F, Zhu Y, Lu J, Ni Z, Zhang Q, Wu Y, Liu G, Wu Z, Qu C, Gail MH.
Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China.
Carcinogenesis. [Epub ahead of print], 2013.
[Journal]
11)  Kwon SM, Kim DS, Won NH, Park SJ, Chwae YJ, Kang HC, Lee SH, Baik EJ, Thorgeirsson SS, Woo HG.
Genomic copy number alterations with transcriptional deregulation at 6p identify an aggressive HCC phenotype.
Carcinogenesis. 2013.
[Journal]
12)  Xin H, Ambe CM, Hari DM, Wiegand GW, Miller TC, Chen J, Anderson AJ, Ray S, Mullinax JE, Koizumi T, Langan RC, Burka D, Herrmann MA, Goldsmith PK, Stojadinovic A, Rudloff U, Thorgeirsson SS, Avital I.
Label-retaining liver cancer cells are relatively resistant to sorafenib.
Gut. [Epub ahead of print], 2013.
[Journal]
13)  Marquardt JU, Thorgeirsson SS.
Linking MLL and the HGF-MET signaling pathway in liver cancer.
J. Clin. Invest. 123: 2780-3, 2013.
[Journal]
14)  Marquardt JU, Thorgeirsson SS.
Sall4 in "stemness"-driven hepatocarcinogenesis.
N. Engl. J. Med. 368: 2316-8, 2013.
[Journal]
15)  Marquardt JU, Fischer K, Baus K, Kashyap A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, Thorgeirsson SS, Galle PR, Strand S.
SIRT6 dependent genetic and epigenetic alterations are associated with poor clinical outcome in HCC patients.
Hepatology. [Epub ahead of print], 2013.
[Journal]
16)  Xin HW, Ambe CM, Ray S, Kim BK, Koizumi T, Wiegand GW, Hari D, Mullinax JE, Jaiswal KR, Garfield SH, Stojadinovic A, Rudloff U, Thorgeirsson SS, Avital I.
Wnt and the cancer niche: paracrine interactions with gastrointestinal cancer cells undergoing asymmetric cell division.
J Cancer. 4: 447-57, 2013.
[Journal]
17)  Jaiswal KR, Xin HW, Anderson A, Wiegand G, Kim B, Miller T, Hari D, Ray S, Koizumi T, Rudloff U, Thorgeirsson SS, Avital I.
Comparative testing of various pancreatic cancer stem cells results in a novel class of pancreatic-cancer-initiating cells.
Stem Cell Res. 9: 249-60, 2012.
[Journal]
18)  Andersen JB, Thorgeirsson SS.
Genetic profiling of intrahepatic cholangiocarcinoma.
Curr. Opin. Gastroenterol. 28: 266-72, 2012.
[Journal]
19)  Coulouarn C, Corlu A, Glaise D, Guénon I, Thorgeirsson SS, Clément B.
Hepatocyte-Stellate Cell Cross-Talk in the Liver Engenders a Permissive Inflammatory Microenvironment That Drives Progression in Hepatocellular Carcinoma.
Cancer Res. 72: 2533-42, 2012.
[Journal]
20)  Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH, Qin LX, Tang ZY, He P, Hunter KW, Thorgeirsson SS, Meltzer PS, Wang XW.
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival.
Gastroenterology. 142: 957-966.e12, 2012.
[Journal]
21)  Marquardt JU, Seo D, Gómez-Quiroz LE, Uchida K, Gillen MC, Kitade M, Kaposi-Novak P, Conner EA, Factor VM, Thorgeirsson SS.
Loss of c-Met accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways.
Biochim. Biophys. Acta. 1822: 942-51, 2012.
[Journal]
22)  Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow BJ, Manway L, Maira SM, Thorgeirsson SS, Mischel PS, Thomas G, Kozma SC.
mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma.
Sci. Transl. Med. 4: 139ra84, 2012.
[Journal]
23)  Wang P, Dong Q, Zhang C, Kuan P, Liu Y, Jeck WR, Andersen JB, Jiang W, Savich GL, Tan T, Auman JT, Hoskins JM, Misher AD, Moser CD, Yourstone SM, Kim JW, Cibulskis K, Getz G, Hunt HV, Thorgeirsson SS, Roberts LR, Ye D, Guan K, Xiong Y, Qin L, Chiang DY.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Oncogene. [Epub ahead of print], 2012.
[Journal]
24)  Zhang J, Espinoza LA, Kinders RJ, Lawrence SM, Pfister TD, Zhou M, Veenstra TD, Thorgeirsson SS, Jessup JM.
NANOG modulates stemness in human colorectal cancer.
Oncogene. [Epub ahead of print], 2012.
[Journal]
25)  Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS.
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma.
Hepatology. 55: 1443-52, 2012.
[Journal]
26)  Thorgeirsson SS.
The central role of the c-Met pathway in rebuilding the liver.
Gut. 61: 1105-6, 2012.
[Journal]
27)  Zheng X, Vittar NB, Gai X, Fernandez-Barrena MG, Moser CD, Hu C, Almada LL, McCleary-Wheeler AL, Elsawa SF, Vrabel AM, Shire AM, Comba A, Thorgeirsson SS, Kim Y, Liu Q, Fernandez-Zapico ME, Roberts LR.
The transcription factor GLI1 mediates TGFß1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism.
PLoS ONE. 7: e49581, 2012.
[Journal]
28)  Ozaki T, Matsubara T, Seo D, Okamoto M, Nagashima K, Sasaki Y, Hayase S, Murata T, Liao XH, Hanson J, Rodriguez-Canales J, Thorgeirsson SS, Kakudo K, Refetoff S, Kimura S.
Thyroid regeneration: characterization of clear cells after partial thyroidectomy.
Endocrinology. 153: 2514-25, 2012.
[Journal]
29)  Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, Zhao X, Andersen JB, Ye QH, Jia HL, Qin LX, Yamashita T, Woo HG, Kim YJ, Kaneko S, Tang ZY, Thorgeirsson SS, Wang XW.
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.
Hepatology. 56: 1792-803, 2012.
[Journal]
30)  Xin HW, Hari DM, Mullinax JE, Ambe CM, Koizumi T, Ray S, Anderson AJ, Wiegand GW, Garfield SH, Thorgeirsson SS, Avital I.
Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division.
Stem Cells. 30: 591-8, 2012.
[Journal]
31)  Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, Tang ZY, Sun Z, Harris CC, Thorgeirsson SS.
Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.
Gastroenterology. 140: 1063-70, 2011.
[Journal]
32)  Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, Thorgeirsson SS, Wiltrout RH.
Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors.
Cancer Res. 71: 2718-27, 2011.
[Journal]
33)  Woo HG, Park ES, Thorgeirsson SS, Kim YJ.
Exploring genomic profiles of hepatocellular carcinoma.
Mol. Carcinog. 50: 235-43, 2011.
[Journal]
34)  Yang JD, Seol SY, Leem SH, Kim YH, Sun Z, Lee JS, Thorgeirsson SS, Chu IS, Roberts LR, Kang KJ.
Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling.
J. Korean Med. Sci. 26: 1428-38, 2011.
[Journal]
35)  Coulouarn C, Factor VM, Conner EA, Thorgeirsson SS.
Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer.
Carcinogenesis. 32: 1434-40, 2011.
[Journal]
36)  Marquardt JU, Raggi C, Andersen JB, Seo D, Avital I, Geller D, Lee Y, Kitade M, Holczbauer A, Gillen MC, Conner EA, Factor VM, Thorgeirsson SS.
Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways.
Hepatology. 54: 1031-42, 2011.
[Journal]
37)  Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, Thorgeirsson SS.
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer.
J. Hepatol. 54: 311-9, 2011.
[Journal]
38)  Lee Y, Judge AD, Seo D, Kitade M, Gómez-Quiroz LE, Ishikawa T, Andersen JB, Kim B, Marquardt JU, Raggi C, Avital I, Conner EA, Maclachlan I, Factor VM, Thorgeirsson SS.
Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response.
Oncogene. 30: 4175-84, 2011.
[Journal]
39)  Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, Vogel H, Sylvester KG, Thorgeirsson SS, Grompe M, Sage J.
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway.
J. Exp. Med. 208: 1963-76, 2011.
[Journal]
40)  Yang JD, Sun Z, Hu C, Lai J, Dove R, Nakamura I, Lee JS, Thorgeirsson SS, Kang KJ, Chu IS, Roberts LR.
Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival.
Genes Chromosomes Cancer. 50: 122-35, 2011.
[Journal]
41)  Thorgeirsson SS.
The almighty MYC: Orchestrating the micro-RNA universe to generate aggressive liver cancer.
J. Hepatol. 55: 486-7, 2011.
[Journal]
42)  Hwang C, Matoso A, Corney DC, Flesken-Nikitin A, Körner S, Wang W, Boccaccio C, Thorgeirsson SS, Comoglio PM, Hermeking H, Nikitin AY.
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.
Proc. Natl. Acad. Sci. U. S. A. 108: 14240-5, 2011.
[Journal]
43)  Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW.
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.
Cancer Res. 70: 10202-12, 2010.
[Journal]
44)  Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS.
An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer.
Sci Transl Med. 2: 54ra77, 2010.
[Journal]
45)  Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, Marquardt JU, Kitade M, Durkin ME, Raggi C, Woo HG, Conner EA, Avital I, Maclachlan I, Factor VM, Thorgeirsson SS.
Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma.
Cancer Res. 70: 8264-9, 2010.
[Journal]
46)  Marquardt JU, Factor VM, Thorgeirsson SS.
Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.
J. Hepatol. 53: 568-77, 2010.
[Journal]
47)  Schuster A, Schilling T, De Laurenzi V, Koch AF, Seitz S, Staib F, Teufel A, Thorgeirsson SS, Galle P, Melino G, Stremmel W, Krammer PH, Müller M.
ΔNp73β is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria.
Cell Cycle. 9: 2629-39, 2010.
[Journal]
48)  Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ, Yi NJ, Suh KS, Lee KU, Park ES, Thorgeirsson SS, Kim YJ.
Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma.
Cancer Res. 70: 3034-41, 2010.
[Journal]
49)  Factor VM, Seo D, Ishikawa T, Kaposi-Novak P, Marquardt JU, Andersen JB, Conner EA, Thorgeirsson SS.
Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice.
PLoS ONE. 5, 2010.
[Journal]
50)  Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, Thorgeirsson SS.
Progenitor-derived hepatocellular carcinoma model in the rat.
Hepatology. 51: 1401-9, 2010.
[Journal]
51)  Marquardt JU, Thorgeirsson SS.
Stem cells in hepatocarcinogenesis: evidence from genomic data.
Semin. Liver Dis. 30: 26-34, 2010.
[Journal]
52)  Zimonjic DB, Zhou X, Lee J, Ullmannova-Benson V, Tripathi V, Thorgeirsson SS, Popescu NC.
Acquired genetic and functional alterations associated with transforming growth factor beta type I resistance in Hep3B human hepatocellular carcinoma cell line.
J. Cell. Mol. Med. 13: 3985-92, 2009.
[Journal]
53)  Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, Conner EA, Factor VM, Roskams T, Thorgeirsson SS.
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis.
Cancer Res. 69: 2775-82, 2009.
[Journal]
54)  Wang XW, Thorgeirsson SS.
Genome-based predictors for HCC outcomes: a matter of tumor and/or stroma.
J. Hepatol. 51: 596-597, 2009.
[Journal]
55)  Woo HG, Park ES, Lee JS, Lee YH, Ishikawa T, Kim YJ, Thorgeirsson SS.
Identification of potential driver genes in human liver carcinoma by genomewide screening.
Cancer Res. 69: 4059-66, 2009.
[Journal]
56)  Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS.
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties.
Oncogene. 28: 3526-36, 2009.
[Journal]
57)  Ishibe S, Karihaloo A, Ma H, Zhang J, Marlier A, Mitobe M, Togawa A, Schmitt R, Czyczk J, Kashgarian M, Geller DS, Thorgeirsson SS, Cantley LG.
Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology.
Development. 136: 337-45, 2009.
[Journal]
58)  Zimonjic DB, Ullmannova-Benson V, Factor VM, Thorgeirsson SS, Popescu NC.
Recurrent and nonrandom DNA copy number and chromosome alterations in Myc transgenic mouse model for hepatocellular carcinogenesis: implications for human disease.
Cancer Genet. Cytogenet. 191: 17-26, 2009.
[Journal]
59)  Wang XW, Thorgeirsson SS.
Transcriptome analysis of liver cancer: ready for the clinic?.
J. Hepatol. 50: 1062-4, 2009.
[Journal]
60)  del Castillo G, Factor VM, Fernandez M, Alvarez-Barrientos A, Fabregat I, Thorgeirsson SS, Sanchez A.
Deletion of the Met tyrosine kinase in liver progenitor oval cells increases sensitivity to apoptosis in vitro.
Am. J. Pathol. 172: 1238-47, 2008.
[Journal]
61)  Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS.
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
Gastroenterology. 135: 1322-32, 2008.
[Journal]
62)  Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, Kim W, Park SC, Chung YJ, Kim BG, Yoon JH, Lee HS, Kim CY, Yi NJ, Suh KS, Lee KU, Chu IS, Roskams T, Thorgeirsson SS, Kim YJ.
Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma.
Clin. Cancer Res. 14: 2056-64, 2008.
[Journal]
63)  Gomez-Quiroz LE, Factor VM, Kaposi-Novak P, Coulouarn C, Conner EA, Thorgeirsson SS.
Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis.
J. Biol. Chem. 283: 14581-9, 2008.
[Journal]
64)  Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, Guerrero RB, Aderca I, Isomoto H, Garrity-Park MM, Zou H, Shire AM, Nagorney DM, Sanderson SO, Adjei AA, Lee JS, Thorgeirsson SS, Roberts LR.
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.
Hepatology. 47: 1211-22, 2008.
[Journal]
65)  Coulouarn C, Factor VM, Thorgeirsson SS.
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.
Hepatology. 47: 2059-67, 2008.
[Journal]
66)  László V, Dezso K, Baghy K, Papp V, Kovalszky I, Sáfrány G, Thorgeirsson SS, Nagy P, Paku S.
Triiodothyronine accelerates differentiation of rat liver progenitor cells into hepatocytes.
Histochem. Cell Biol. 130: 1005-14, 2008.
[Journal]
67)  van Hagen JM, van der Geest JN, van der Giessen RS, Lagers-van Haselen GC, Eussen HJ, Gille JJ, Govaerts LC, Wouters CH, de Coo IF, Hoogenraad CC, Koekkoek SK, Frens MA, van Camp N, van der Linden A, Jansweijer MC, Thorgeirsson SS, De Zeeuw CI.
Contribution of CYLN2 and GTF2IRD1 to neurological and cognitive symptoms in Williams Syndrome.
Neurobiol. Dis. 26: 112-24, 2007.
[Journal]
68)  Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS, Popescu NC.
DLC-1:a Rho GTPase-activating protein and tumour suppressor.
J. Cell. Mol. Med. 11: 1185-207, 2007.
[Journal]
69)  Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran E, Thorgeirsson SS, Mazzaferro V, Bruix J, Martignetti JA, Llovet JM, Friedman SL.
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.
J. Hepatol. 46: 645-54, 2007.
[Journal]
70)  Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, Factor VM, Thorgeirsson SS.
Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis.
Cancer Res. 67: 9844-51, 2007.
[Journal]
71)  Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS.
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.
J. Clin. Invest. 117: 2713-22, 2007.
[Journal]
72)  Mayhew CN, Carter SL, Fox SR, Sexton CR, Reed CA, Srinivasan SV, Liu X, Wikenheiser-Brokamp K, Boivin GP, Lee JS, Aronow BJ, Thorgeirsson SS, Knudsen ES.
RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis.
Gastroenterology. 133: 976-84, 2007.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 11/13/2013.